Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a multicentric phase II study of Mabthera (rituximab) in children and adolescents
with relapsed and refractory B-cell NHL/L3ALL. The primary objective is to determine the
response rate of Rituximab as single agent in relapsed or refractory Burkitt lymphoma, L3
acute leukemia, large B-cell lymphoma and non subclassified aggressive B-cell NHL